The EXTRACT study enrolled a large and representative cohort of patients with NSCLC and EGFR ex20ins mutations who received mobocertinib, reporting on treatment management patterns, real‐world outcomes, and safety. This evidence concerns the gene EGFR and non-small cell lung carcinoma.